Fate Therapeutics receives $15M CIRM grant for lupus trial
Fate Therapeutics announced a $15 million CIRM grant for its Phase 2 lupus nephritis trial, advancing its FT819 off-the-shelf CAR T-cell therapy. The funding is intended to broaden access to this potentially curative treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed